Radiopharmaceutical developer Navidea Biopharmaceuticals said that studies involving its Lymphoseek and NAV4694 radiopharmaceuticals will be presented at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
Navidea said there will be 10 oral and poster presentations highlighting the comparative performance of its Lymphoseek radiopharmaceutical against commonly used nonreceptor-targeted colloidal materials, as well as results demonstrating the efficacy of lymphatic mapping in breast, melanoma, and head and neck cancers.
In addition, four oral and poster presentations focused on the company's NAV4694 beta-amyloid PET imaging candidate will report performance and comparative results from clinical studies in Alzheimer's disease, Navidea said.
